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INVESTIGATION OF HLA DRB1 ALLELES IN THE TREATMENT OF 
CHRONIC HEPATITIS B PATIENTS 
SUMMARY 
Chronic hepatitis B virus (HBV) infection is a global health problem with an 
estimated 350 million people chronically infected worldwide. Considerable evidence 
suggests that the progression of hepatitis B virus infection is influenced not only by 
the viral genotype and the level of viremia but also host genetic factors play a 
significant role in the pathogenesis and clinical outcome of chronic HBV infection in 
several ethnic groups. It is mentioned that both cellular and humoral responses are 
required for viral clearance. Hence, the aim of this study is to investigate the 
association between the polymorphisms of HLA-DRB1 alleles and viral hepatitis B 
in Turkish population.  
In this study 324 patients were included; 63.4% male (n=204), 36.6% female 
(n=120) and, where 23.5% (n=76) of patients being HBe antigen positive, 23.8% 
(n=77) having cirrhosis. The median age was 44 years (age between 39-49), median 
follow up time was 86.5 months. In the control group 150 healthy cases were 
included (for DRB1*07 allele). HLA-DRB1 alleles in 324 patients with chronic 
hepatitis B and 150 controls were analyzed using the polymerase chain 
reaction/sequence specific primer (PCR/SSP) technique.  
In our group of patients, DRB1 alleles were not related to active or inactive disease, 
or interferon treatment response or virologic breakthroughs observed during 
nucleoside analog treatments. On the other hand we have found statistically 
significant frequency of DRB1*07 allele (p=0.003) in our case-control study. 
Moreover, our data showed that, patients who had DRB1*07 allele had lower 
probability to have cirrhosis (likelihood ratio chi square: 4.17, p=0.04), suggesting 
that DRB1*07 might be associated with low risk of cirrhosis development.   
In this case, DRB1*07 allele may be one of the host factors, which influences 
immune response to HBV, by self-limiting cirrhosis, one of the main complications 
of chronic HBV. Findings from this thesis are expected to acknowledge the 
relationship between chronic HBV infection and HLA DRB1 polymorphisms. 
Additional study is needed to validate these findings and to further explore the 
genetic pathogenesis of HBV infection. 
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KRONİK HEPATİT B HASTALARIN TEDAVİSİNDE HLA DRB1 
ALLELERİN İNCELENMESİ 
ÖZET 
Kronik hepatit B virüs enfeksiyonu dünyada yaklaĢık 350 milyon kiĢiyi enfekte eden, 
en yaygın bulaĢıcı hastalıklardan birisi olarak global bir sağlık sorunu teĢkil 
etmektedir. Yapılan çalıĢmalar, hepatit B virüs enfeksiyonun‟un progresyonunda 
sadece viral genotip ve vireminin değil, aynı zamanda konak genetik faktorlerinin de 
oldukça önemli rol oynadığını vurgulamaktadır. Aynı zamanda, hem hücresel hem de 
humoral immün yanıtın virüsün eredike edilmesi için gerekli olduğu birçok deneysel 
çalıĢmada gösterilmektedir.  
Bu nedenle, bu çalıĢmanın amacı, Türk toplumunda HLA-DRB1 allelleri ve viral 
hepatit B klinik seyri arasındaki iliĢkiyi araĢtırmaktır. Bu çalıĢmaya, 324 hasta dahil 
edildi; 63.4% erkek (n=204), 36.4% kadın (n=120) ve 23.5% (n=76) HBe antigeni 
pozitif hastalar ile 23.8% (n=77) siroz olan hastalar. Ortalama yaĢ 44 yıl (39-49 yaĢ ) 
arası, ortalama takip süresi ise 86.5 ay idi. Kontrol grubunda ise 150 sağlıklı kiĢi 
dahil edildi (DRB1*07). Kronik hepatit B olan 324 hastada ve 150 sağlıklı kiĢide 
HLA-DRB1 allelleri polimeraz zincir reaksiyonu/sekans spesifik primer (PCR/SSP)  
tekniği kullanılarak analiz edildi. 
Bu çalıĢmada, aktif ya da inaktif hastalık veya interferon tedavisine yanıt veya 
nükleozid analog tedavisi sırasında gözlenen virolojik kırılma (breakthrough) 
olayları ile DRB1 allellerinin arasında anlamlı iliĢki gözlemlenmemiĢtir. Diğer 
taraftan vaka-kontrol grubumuzda DRB1*07 alleli için istatistiksel olaraka anlmalı 
değerler elde edildi (p=0.003). Dahası, elde dilen veriler sonucunda, DRB1*07 alleli 
saptanan hastalarda siroz anlamlı olarak daha nadir gözlemlenmiĢtir (likelihood ratio 
chi square:4.17,  p=0.04). 
Bu durumda, DRB1*07 alleli HBV immun yanıtını etkileyen önemli konak 
faktörlerden biri olabilir. Ayrıca, kronik HBV ana komplikasyonlar‟dan biri olan 
sirozun kendi kendini sınırlamasında oldukça önemli rol oynadığı düsünülmektedir. 
Bu çalıĢma, kronik HBV ve HLA DRB1 polimorfizmi arasındaki iliĢkinin ortaya 
konmasında yardımcı bilgiler sunmaktadır. HBV‟nin genetik patogenezinin 
anlaĢılması ve bu çalıĢmadaki bulguların doğrulanması için daha büyük hasta 
gruplarında HLA polimorfizmi araĢtırılmalıdır.  
 
  
xxii 
 
 
 
  
1 
 
1. INTRODUCTION 
1.1 Chronic Hepatitis B   
Chronic Hepatitis B virus infection is a major problem causing both acute and 
chronic liver disease by affecting approximately 350 million people worldwide [1]. 
Despite the prophylactic vaccination programs in communities, according to the data 
by the World Health Organisation, an estimated 600 000 people die each year due to 
the acute or chronic consequences of hepatitis B [2,3]. HBV infection may persist 
and culminate in chronic hepatitis B. In adulthood chronicity is observed 
approximately 15% of the cases, but still the factors that determine the HBV 
persistence and clearance are not very well understood [2,3]. However, various host 
conditions such as age of infection, gender, and immune response were observed to 
influence the risk of persistent HBV infection and have shown remarkable clinical 
and pathogenic differences among HBV genotypes. Data obtained to date mentions 
the importance of host immune response in determining the outcomes of HBV 
infection [2,3]. In this line, we aim to delineate the relation between the human 
leukocyte antigen class II molecule and the host immune response of chronic 
hepatitis B virus infection.  
1.2 Genome Organization of Hepatitis B 
Hepatitis B virus (HBV) is a species of the genus Orthohepadnavirus which is a 
prototype member of Hepadnaviridae family of viruses [2]. Partly double stranded 
HBV genome is a circular DNA with about 3,200 nucleotides. The minus strand of 
the virus is almost a complete circle and encodes the structural proteins of the virus; 
whereas the second strand, plus strand, overlaps with most parts of the minus strand 
and encodes some of the structural proteins, but it is shorter in length [4-7]. Once the 
virus invades the body, it binds to the cell surface and penetrates to the host cells 
with the help of its envelope proteins. Inside the plasma membrane of the cell, the 
virus is not degraded but is transported to the nucleus where the partially circular 
DNA is made into covalently closed circular DNA (cccDNA) and the cccDNA 
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functions as a template for RNA synthesis which is then reverse transcribed into an 
open, circular DNA.  
The new formed, circular DNA is subsequently packaged into viral envelopes in the 
endoplasmic reticulum and then transported out of the cell (Figure 1.1) [4-7]. 
 
Figure 1.1 : A simplified diagram of HBV replication [8]. 
Unlike other viruses, HBV does not integrate itself into the host genome but retains a 
core of cccDNA in the nucleus of the cell by transporting some of the newly 
synthesized HBV DNA back to the nucleus as seen in the chronic condition of 
hepatitis B [4-7] causing a continues replication of itself inside the host's cells 
(Figure 1.1) [4-7]. 
There are four open reading frames (four known genes) running in one direction 
without any noncoding regions and these open reading frames (ORFs) code for: C, P, 
X, and S genes. These overlapping ORFs in the genome are responsible for the 
transcription and expression of seven different hepatitis B proteins [3].  
The C gene is divided into a core (codes the structural protein of the nucleocapsid-
HBcAg) and a precore (codes the HBeAg) region by 2 in-frame initiating AUG start 
codons. The function of nucleocapsid protein is to enclose the viral DNA and the 
DNA polymerase that is essential for HBV replication. HBeAg which is produced by 
the proteolytic processing of the pre-core protein, [9-11] is considered to be a marker 
for the viral replication; hence, seroconversion from HBeAg to anti-HBe positivity 
usually indicates a low level of viral production and low level of serum HBV DNA. 
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The gene P also known as HBV 
polymerase is an enzyme with 
multiple viral life related functions. 
Its primary polymerase activity 
enables the synthesis of DNA using 
either RNA or DNA templates, its 
RNase H activity provides the 
degradation of the RNA strand of 
RNA-DNA hybrids, and the 
packaging of the RNA pregenome 
into nucleocapsids [2,3].
 
                                                                        Figure 1.2 : Genomic structure of HBV [8]. 
 
X - a transactivator of viral transcription, is thought to play a major role in 
hepatocellular carcinoma (HCC) development [9,13]. In vitro studies presented that 
HBx is implicated as one of the causative agents in carsinogenesis by being 
responsible for the activation of both cellular immune response and viral promoter 
regions, however, its contribution to tumor invasion and metastasis in the course of 
HBV infection has not been established. A study done in Turkey, which successfully 
generated stable transmission and expression of the hepatitis B virus total genome in 
hybrid transgenic mice until F10 generation, showed that even in the presence of 
HBx protein expression in hepatocytes there was not any observation of neoplasia 
during the life span and HCC development [12]. The observation of distinct results 
on susceptibility to hepatocarcinogenesis among independent study groups was 
mentioned to be due to mouse strains used and other possibilities such as deletions 
in the sequence of HBx gene or trangene instegration sites of HBV [12]. 
The S gene codes for the surface antigen (HBsAg) (Figure 1.2), which is one long 
open reading frame that encodes 3 polypeptides of the surface antigen (preS1, preS2 
and S - produced from the alternative translation start sites) [3,9-11,14]. The most 
significant part of HBV genome among the four ORFs (C, P, X and S genes), is the 
HBsAg gene, which is particularly important because the S protein product contains 
an epitope that generates a protective immune response against the virus, and is thus 
key in the current therapy of HBV infection [3,9]. 
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1.2.1 Genotypes and mutations of HBV 
According to overall nucleotide sequence variation, in the genome of HBV seven 
genotypes were defined [7,9]. The figure below shows the genotypes together with 
its serotypes with distinct geographical distribution (Figure 1.3) [7,9].
 
Figure 1.3 : Genotypes of Hepatitis B virus [7,9]. 
Amongst the genotypes, A-G, the most frequently observed genotype in our country 
is the genotype D [15] and in many studies it is shown that the clinical outcome of 
the hepatitis B disease differs in accordance with genotypes [15].
 
For instance, the 
study conducted in Turkish population including genotype D demonstrated that 
isolates from five AntiHBe positive patients contained specific mutations, which 
were reported to increase viral replication and result in a poor prognosis [15].
 
The 
correlation between HBV genotypes and clinical outcome of patients with HBV in 
Chinese population was shown that patients with genotype C infection have a more 
aggressive clinical phenotype than those with genotype B infection [16].
 
Clinical 
studies also revealed that, the rate of HBsAg clearance was higher in genotype A 
than genotype D patients [16]. 
The gene mutations are summarized according to the ORFs: S gene mutations: 
Mutations in the HBV surface protein that facilitate the escape from host immunity 
are responsible for the failure of immune prophylaxis in infants who received HBV 
vaccine and in liver transplant recipients who received hepatitis B immune globulin 
Genotypes of Hepatitis B Virus 
Type Subtype Geographical Distribution 
A adw, adw2, ayw1 US, Northern Europe, Africa 
B adw2, ayw1 China, Indonesia, Vietnam 
C adr, ayr China, Korea, Japan, Vietnam 
D ayw2, ayw3 Mediterranian, Middle East, India 
E ayw4 West Africa 
F adw4 Polynesia, US (rare) 
G adw4 Europe, US (rare) 
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[3,17].
 The common amino acid mutations 125 (M → T) and 127 (T → P) were 
observed in surface antigen in Turkish population [18]. Another study have revealed 
four novel mutations sL97S, sL98S, sG102R, and sA159P) in the preS/S gene 
region. However, the biological importance of these mutations is not well determined 
[19]. Another clinically importat mutation was shown to be G145R present on the S 
region of the HBV genome. G145R mutation results not only in the loss of group-
specific antigenic determinant a, which is the main target of the vaccine response, but 
also in impaired S secretion and decreased virion stability [14]. 
C gene mutations: The mutations in the pre-core region may result in inability to 
produce HBeAg (G>A at nt 1896), and this affects disease severity or serological and 
clinical manifestations [9]. HBeAg – negative variants are common for genotypes D 
as observed in Turkish population [5,13,17]
 
Substitutions in the core region are 
shown to concentrate in B cell epitopes in progressive disease and in T helper cell 
epitopes during clinical remission [12].
 
P gene mutations can affect replicative 
efficiency and resistance to antiviral therapy, and these mutations are detected after 
the use of the reverse transcriptase inhibitor drugs [9]. 
The largest ORF in the HBV genome, which encodes for the hepatitis B polymerase 
protein (P gene) has been divided into four characterized domains; a terminal protein 
(the N-terminus portion of the protein acts in priming (-) DNA strand synthesis and 
ends up covalently linked to the 5' end of the (-) DNA strand, and termed primase), a 
spacer region (no enzymatic function, just acts as a spacer between the first and third 
domains), a reverse transcriptase (encodes for the RNA and DNA dependent 
polymerase activity) and an RHase H (possesses its RNase H activity) domain (Table 
1.1) [9].  
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Table 1.1 : Clinically important hepatitis B virus (HBV) mutations [9]. 
Clinically important hepatitis B virus (HBV) mutations  
MUTATION LOCATION IN THE HBV 
GENOME 
RISK FACTORS FOR MUTATION SIGNIFICANTE 
YMDD and 
multiple others 
P (polymerase) gene Previous treatment with nucleoside 
analogues  
Development of drug 
resistance 
Precore or core  C (core) gene More common in Asia and 
Southern Europe (30%-90%) than 
in the United States (10%-40%) 
Failure of HBV e antigen 
secretion but with a 
remaining risk for 
progressive liver disease 
Vaccine 
escape 
‘’a’’ determinant of 
the S gene  
HBV vaccine or immune globulin 
recipients 
Possibly increased risk of 
hepatocellular carcinoma or 
prolonged HBV infection  
 
HBV Polymerase 
Terminal Protein Spacer Reverse Transcriptase RNase H 
Figure 1.4 : Mutations in HBV confer resistance to antiviral drugs [20]. 
The most common drug-resistance mutation appears in the YMDD locus of the 
reverse transcriptase domain of the HBV DNA polymerase gene, and leads to the 
substitution of methionine by valine or isoleucine, which is denoted by reverse 
transcriptase M204V/I [21-24]. These mutations decrease the capacity of viral 
replication. On the other hand, although the presence of other compound mutations 
(rtL180M, rt173L, rtL80V/I, rtL82M, rtF166L, rtA200V ve rtV173L) may result in 
an increase of viral replication. Adefovir dipivoxil resistance mutations on the DNA 
polymerase are positioned in the 181st and 236th residues by the conversion of 
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alanine to valine (A181V) and asparagine to threonine (N236T), respectively [21-
24]. 
X gene mutations:  To our knowledge, X protein may alter host gene expression by 
causing the development of HCC [9,13]. X gene affects the control of transcription 
by acting as a transactivator of various viral and cellular promoter/enhancer factors 
and can mediate the activation of signal transduction pathways [9,13]. Any mutation 
on the X gene can therefore affect DNA repair, cell cycle control, and apoptosis 
[9,13]. Even though various roles of the X gene is attributed, its exact function in the 
cell is still unknown, so the clinical significance of HBx mutations are not clearly 
understood yet [9,13]. 
1.3 The Epidemiology of Hepatitis B 
1.3.1 Transmission of HBV infection  
Transmission of hepatitis B virus results from the exposure to infectious blood or 
body fluids containing blood, where the possible forms of transmission include 
sexual contact, blood transfusions, re-use of contaminated needles and syringes, and 
vertical transmission from mother to child during childbirth [25]. In countries with 
high prevalence of HBV infection, the transmission of hepatitis B infection is 
observed more frequently in prenatal period and most common at birth through blood 
and infected fluids. In this case, the rate of transmission of infection to infants from 
HBeAg positive and negative mother is about 70-90% and 5-20%, respectively. After 
2-3 months, antigemia is observed in infants. If the blood is positive for HBV surface 
antigen but negative for HBeAg, the risk of HBV transmission from a single needle 
stick is 1% to 6% and 22% to 40% if positive for both antigens [7,26]. 
1.3.2 HBV infection worldwide 
HBV infection is highly prevalent in Asia, sub-Saharan Africa, and other areas of the 
developing world, but less in United States, except in Alaskan natives and 
immigrants (45% and 80%) from regions of high prevalence. A study done in 
Turkish population with 2683 controls under age 30 (in 8 different regions of 
Turkey), showed that the rate of positivity of HBsAg was 5.4% and for the Anti 
HBcIgG, it was 17% and the rate of positivity for HBsAg in transplant cases was 
approximately 4.9% [7, 25,27-29]. 
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1.4 Immunopathogenesis of Hepatitis B virus  
The course of hepatitis B virus infection appears to be determined by variations in 
viral virulence and by the host immune response [host factors like the major 
histocompatibility complex [30] (MHC)]. Considerable evidence suggests that host 
genetic factor plays a significant role in the pathogenesis and clinical outcome of 
chronic HBV infection in several ethnic groups, where the damage of the liver is 
observed mostly associated with the host`s immune response [2-3]. 
Hepatitis B virus infection may either be acute or chronic. The figure below shows 
the clinical outcome of Hepatitis B virus infection (Figure 1.5). 
Figure 1.5 : Outcome of Hepatitis B Virus Infection [2-3]. 
Acute infection with hepatitis B virus is associated with acute viral hepatitis where 
the infection may be entirely asymptomatic and may go unrecognized and the 
immune response is normal (self-limiting). However, the insufficiency of immune 
response against the virus leads to chronic hepatitis B virus infection (long-standing). 
Roughly about 5-10% of chronic hepatitis B is observed in patients after they 
experience the infection. Chronic hepatitis B virus may be either asymptomatic or 
associated with a chronic inflammation of the liver, causing cirrhosis and liver cancer 
(hepatocellular carcinoma) [31, 32].  
Both innate immunity and adaptive immunity are involved during infection invasion, 
where the immune response to HBV-encoded antigens is responsible both for viral 
clearance and for disease pathogenesis during this infection. Innate immunity gets 
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triggered immediately after infection to limit the spread of the pathogen and initiate 
efficient development of the adaptive immune response. To date, there are several 
real animal model of HBV infection in the chimpanzee and mice. The experiments in 
chimpanzees with acute hepatitis B from the period of logarithmic replication of 
virus (5-7 weeks) showed that there was not observed any activation of innate 
immunity [33,34].
 
In several virus infections when the virus enters the host, 
recognition of viruses by Toll like receptors (TLR) result in secretion of interferon 
alpha/beta showing an anti-viral activity by triggering intracellular response 
pathways, where these cytokines increase the expression of cell surface MHC I 
related genes [4,35].
 
Thus, cytokines induce an efficient triggering of immunity and 
the fragments of viruses within the infected cells are then displayed to cytotoxic T 
cells by MHC Class I molecules. Cytotoxic T cells kill the infected cells and lead to 
elimination of them. However, in hepatitis B infection there is no sign of innate 
immune response even in the first 5-7 weeks of disease. Moreover, several studies 
show that both in chimpanzees and the woodchuck model until the logarithmic 
increase of HBV DNA in the liver or the peripheral circulation in silent period, there 
is no evidence of activation of the innate immune system and the logarithmic 
replication of HBV DNA to 10
10 
copy/ml result in infection of all hepatocytes 
(Figure 1.6) [4-6,10,13,30,34].
 
 
Figure 1.6 : Kinetics of innate and adaptive immune response during hepadnavirus infection. HBV, 
hepatitis B virus; WHBV, woodchuck HBV [4]. 
In the course of hepatitis B virus infection, the observation of logarithmic increase of 
HBV DNA in blood results in the activation of the adaptive immune response. 
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Subsequently, the stimulation of CD8+ T lymphocytes lead to clinical outcome of 
hepatitis B infection together with the increase of enzymes involved in this period.  
The secretion of the different IgG subclass profiles of anti-HBs, anti-HBc, and anti-
HBe in HBV infection status were revealed by CD4+ T cells. CD 4+ cells cause the 
stimulation of anti-HBc antibody, followed by activation of anti-Hbe and anti-preS 
[5,34]. The antibody component of the adaptive immune response, provides a 
defense against virus infection, and as observed T cells are the primary mechanisms 
in the adaptive immune response to clear virus-infected cells. When major 
histocompatibility complex (MHC) restricted, T cells enter the liver and recognize 
antigen, they kill some of the infected cells and secrete IFN-γ, which induces the 
expression of a large number of genes that enhance antigen processing and 
presentation; recruit macrophages, NK (Natural Killer) or dendritic cells, and T cells 
that also produce IFN-γ; and amplify the process [4,6,10,13,30,34,35]. Moreover, 
several studies have shown that cytotoxic T cells response to HBV infection is 
polyclonal and multispecific for acute HBV infection, and these highly coordinated 
cellular and molecular events continue until the infection is terminated (Figure 1.7) 
[5,34]. It is also important to note that the studies in the HBV transgenic mouse 
model revealed that while the depletion of CD4+ T cells result in minor effects in the 
course of HBV infection, the depletion of the CD8+ T cells result in major effects as 
delayed and prolonged virus clearance and final virus elimination [5,34, 36,37]. After 
a long period of infection the reappearance of the CD8+ cells with IFN-γ rapidly 
clear the remaining infected cells as actually observed in acute hepatitis B infection. 
In contrast to the strong and multispecific T cell responses observed during self-
limited HBV infection, the appearance of such an immune response in the patients 
with chronic HBV infection was shown to be highly weak and narrowed 
[5,34,36,37]. Despite of efforts in the field, still the virus specific T cell response in 
chronic HBV infection is poorly understood. The unresponsiveness to virus is 
correlated with many reasons such as T cell deletion, ignorance, T cells dysfunction, 
specific HLA polymorphisms, and abnormal HLA/peptide tetramer binding.  
Although the presence of mutations on genes of HBV may lead to inactivation of T 
cell response, it was shown to occur much less when compared with hepatitis C virus 
[5,34,36,37]. In our study, we aim to understand the association of HLA alleles with 
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the course of chronic HBV infection one of the reasons of T cell failure mentioned 
above. 
Figure 1.7 : Immune responses against HBV and effects of chronic HBV infection [34]. 
1.5 Clinical Outcome and Treatment of Chronic Hepatitis B Virus Infection 
Based on the virus and host interactions, the natural history of perinatally acquired 
HBV infection in carriers who acquire the virus early in life can be divided into four 
dynamic phases (Figure 1.8) [38]. 
 
 
 
 
 
12 
 
 
 
 
 
 
 
 
Figure 1.8 : Natural history of perinataly acquierd HBV infection [38]. 
The immune tolerance phase is associated with high serum levels of HBV DNA 
(<10
7
 copies/ml), limited immunological reactivity to HBV, extensive viral 
replication, and expression of HBeAg. In immune tolerant cases with positive 
HBeAg, the level of alanine aminotransferase (ALT) in serum is presented normal 
for a long period and no symptoms are observed, although liver of some young HBV 
carriers who have immune tolerance, shows some abnormalities [3,9,14,25].
 
Chronic 
HBV patients show increased levels of ALT, triggering the immune clearance and 
the majority of HBV carriers seroconvert from HBeAg to anti-HBe [3,9,14,25]. After 
HBeAg seroconversion, patients usually evolve into the low replication phase that is 
characterized by absence of HBeAg, presence of anti-HBe, persistently normal ALT 
levels, low or undetectable serum HBV DNA (<10
4
 copies/ml), and even HBsAg 
seroclearance with mild hepatitis and minimal fibrosis. Patients negative for HBeAg 
are considered to have non-replicative HBV infection, and their serum ALT levels 
are observed to be normal or nearly normal [3,9,14,25]. 
HBV could replicate in the absence of HBeAg and the reactivation of HBV may 
occur spontaneously or as a consequence of immunosuppression. In this phase, 
detectable HBV DNA (<10
4
 copies/ml), elevated serum ALT, and progressive liver 
disease will develop [3,9,14,25]. 
In addition, the presence of high serum levels of ALT in patients with acute hepatitis 
B virus infection in a period after 6 month is considered as a chronic Hepatitis B 
infection (Figure 1.9 & Figure 1.10) [39]. 
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Figure 1.9:Clinical Outcome of Acute HBV [40].Figure 1.10:Clinical Outcome of Chronic HBV[40]. 
Patients with acute HBV infection does not usually require treatment because they 
clear the infection spontaneously, whereas, treatment of chronic HBV infection may 
be necessary to reduce the risk of cirrhosis and liver cancer, although, none of the 
available drugs are able to clear the infection, they only can stop the virus from 
replicating, thus minimizing cirrhosis and liver damage [41-51]. There are some 
medications currently in use for treatment of active hepatitis B infection, including 
antiviral drugs and immune system modulators Lamivudine, Adefovir dipivoxil 
(Hepsera), tenofovir (Viread), entecavir (Baraclude).Interferon alpha-2a and 
PEGylated interferon alpha-2a (Pegasys- Pegintron). Lamivudine inhibits hepatitis B 
viral DNA synthesis [41-51]. Pretreatment ALT is an important predictor of 
response, with HBeAg conversion occurring in over a third of patients when the ALT 
is greater than five times normal. While Lamivudine (Lam) benefits patients with 
HBeAg-negative chronic hepatitis B, the vast majority of patients relapse once 
treatment is stopped [41-51]. 
Adefovir (Adv) dipivoxil inhibits DNA polymerase activity and reverse 
transcriptase. About 50 - 60 % of HBeAg positive and negative hepatitis B (<67% 
HBV DNA negativity) patients respond to this medication [41-51]. The optimal 
duration of therapy is not yet clear. The negativity of HBV DNA in patients with 
HBV treated with tenofovir (Tdf) and entecavir (Etv) showed a percentage above 90. 
HBeAg negative patients treated with PEGylated interferon alpha-2a showed about 
25% negativity of HBV DNA, 34% seroconversion, and about 3% loss of HBsAg, 
where after the third year 20% of patients show a HBV DNA level below 400 copies 
[41-51]. Additionally, according to the European Association for the Study of the 
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Liver (EASL), while the treatment is not recommended to patients involved in 
immune tolerance group, in the patients with compensated and decompensated 
cirrhosis, independent of DNA level the treatment is recommended. Furthermore, in 
patients with high value of ALT and HBV DNA level over 2000 IU biopsy is 
recommended followed by treatment of chronic HBV infection using antiviral drugs 
and immune modulators [52]. 
1.6 Human Leukocyte Antigen (HLA) 
Human leukocyte antigen (HLA) is the human version of the major 
histocompatibility complex (MHC). It is a large genomic region or gene family that 
consists of more than 140 genes. MHCs play a significant role in the immune system 
and autoimmunity by distinguishing the body's own proteins from proteins made by 
foreign invaders such as viruses and bacteria [53-54]. 
Genes in this complex are categorized into three basic groups: class I, class II, and 
class III, where the HLA region spans 4 x 106 nucleotides on chromosome 6p21.1 to 
p21.3, with HLA class II, HLA class III and HLA class I genes located from the 
centromeric to the telomeric end (Figure 1.11) [54], a region of strong linkage 
disequilibrum containing many other immune response genes. 
Figure 1.11 : Gene map of the human leukocyte antigen (HLA) region [55]. 
Humans have three major MHC class I genes, known as HLA-A, HLA-B, and HLA-
C. These genes are highly polymorphic, which enables the recognition of a great 
diversity of virus and bacteria. MHC class I genes are expressed in all nucleated 
cells. These genes encode two polypeptide chains; α chain & β2-micro-globulin 
(Figure 1.12), where only the α chain is polymorphic [56-57]. HLA class I presents 
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peptides to the cytotoxic T cells via the receptors on the cytotoxic T cells and also 
binds inhibitory receptors on NK cells, thus stimulates immune responses against 
„endogenous‟ antigens and virally infected targets [56,57]. Whereas HLA class II 
molecules are involved in the presentation of „exogenous‟ antigens to T helper cells. 
There are 3 major MHC class II proteins encoded by the HLA known as HLA-DQ, 
HLA-DR, and HLA-DP. These genes provide instructions for making proteins that 
are present almost exclusively on the surface of certain immune system cells, 
specifically on antigen-presenting cells and proteins contain α & β chains both of 
which are polymorphic and encoded in the MHC (Figure 1.13) [56-57]. They present 
antigen fragments to T helper cells by binding to the CD4 receptor on the T helper 
cells and hence trigger an appropriate immune response to fight against foreign 
proteins [54,58,59].
 
In other words, HLA class II genes are expressed as cell surface 
glycoproteins that bind and present peptide epitopes to CD4 T cells, resulting in their 
activation. Each HLA subtype has a specific binding motif that dictates the specific 
range of peptides that can physically bind in a groove on the surface of the HLA 
genes [54,58,59]. There are various crystal structures with HLA-DR1 [69]. These 
structures revealed that these HLAs have allele-specific motifs [69]. The peptide 
binds as a straight extended chain with a pronounced twist interacting with the ά and 
β chains [69]. Peptide specificity of HLA class II proteins comes from the 
determined polymorphic pockets in the peptide-binding cleft. T-cell receptor 
recognition is done by both the peptide and the HLAs [69]. There are some HLA-
DRB1 types that show polymorphism at the T-cell recognition sites without altering 
the peptide binding [69]. Due to these changes at the T-cell recognition residues, a 
weak immune response occurs. Especially HLA-DRB1*07 contains four 
substitutions at the T-cell interaction residues, which are located at beta30, beta 67, 
beta71 and beta86 [69]. 
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Figure 1.12 : The trimolecular complex of TCR, MHC molecule [56].
 
Many autoimmune diseases show strong correlations with particular HLA alleles. 
Studies conducted by many authors have proposed the differential binding of 
pathogenic peptides to allele specific HLA class I glycoproteins as a mechanism of 
disease protection [60-62]. However, the mechanism underlying the correlation of 
particular HLA class II alleles and infectious disease is still unknown. Also the 
details such as whether specific HLA class II glycoproteins are involved, their 
specific binding motifs are present or another immune response is involved in the 
immune response against the infection are not clarified [60-62]. X-ray 
crystallographic structures revealing the interaction between HLA and antigenic 
peptides and studies investigating the biophysical properties of MHC relation with its 
peptides have correlated a potential role for HLA in various autoimmune diseases 
[36]. For instance, a study in Caucasian population showed that DRB1*0401 and 
DRB1*0404; DRB1*0101, DRB1*1001, and DRB1*1402 disease susceptibility 
genes are the major HLA alleles associated with rheumatoid arthritis (RD) [36]. 
Another study, presented that DRB1*1501, which is in linkage disequilibrium with 
DRB1*0101 and DQB1*0602 is strongly linked to multiple sclerosis, an 
inflammatory autoimmune disease in which T cells are reactive towards the myelin 
sheath [36]. Celiac disease that is one of the most studied HLA class II associated 
diseases, is observed to be related with the DQA1*0501/DQB1*0201 being in 
linkage disequilibrium with DRB1*03 [36]. 
Furthermore, various HLA class II molecules were presented to be linked to an 
increase in the insulin dependent diabetes mellitus (IDDM) susceptibility [36]. 
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The immune system uses the HLA complex to differentiate self cells and non-self 
cells, thus protecting the body from several diseases. Table 1.2 shows some disorders 
related to HLA Class I and HLA Class II genes (polymorphisms).  
Table 1.2 : HLA Class I and HLA Class II Related Diseases [36]. 
 Serological 
marker 
Gene  
Spondilartropatie    
Ankylosing spondylitis B27 B*2702, -04, 05 ++++ 
Reiter's Syndrome B27  ++++ 
Acute anterior uveitis B27  +++ 
Reactive arthritis B27  +++ 
Psoriatic arthritis B27  +++ 
Connective Tissue Diseases    
Juvenile arthritis DR8  ++ 
 DR5  ++ 
Rheumatoid arthritis DR4 DRB1*0401, -04, -
05 
+++ 
Sjögren's syndrome DR3  ++ 
Systemic lupus erythematosus    
Whites DR3  + 
Japanese DR2  ++ 
Autoimmune diseases    
Coeliac disease DQ2 DQA1*0501 +++ 
  DQB1*0201  
Chronic active hepatitis  DR3  ++ 
Dermatitis herpetiformis DR3  +++ 
Psoriasis vulgaris Cw6  ++ 
Pemphigus vulgaris DR4 DRB1*0402 +++ 
 DQ1 DQB1*0503  
Bullous pemphigoid variant DQ7 DQB1*0301 + 
Autoimmune Endocrine Disorders    
Diabetes mellitus type 1 DR4 DQB1*0302 +++ 
 DQ8 DRB1*0401, -04  
 DR3  ++ 
 DR2 DQB1*0602 __a 
Hyperthyroidism (Graves') B8  + 
 DR3  + 
Hypertiroidism (Japanese) B35  + 
Adrenal insufficiency DR3  ++ 
1.7 Hepatitis B Virus Infection and HLA   
The observation of different immune responses in patients with hepatitis B virus 
infection has led the scientists to search the MHC (human leukocyte antigen 
presenting cells) complex in HBV infection. In literature, it was mentioned that 
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although the mechanism of susceptibility to chronic HBV infection is not well 
clarified, the course of HBV infection does not appear to be determined only by 
variations in viral virulence but also may be inﬂuenced by the host immune response. 
Several studies shows that host genetic factors and environmental factors involving 
HBV genotype are widely viewed as common basis for the distinct outcomes of 
HBV infection [36,37,60]. In addition, HLA plays a significant role in 
immunological reaction to HBV infection. Although the pathogenesis of chronic 
HBV infection is poorly understood, several experimental evidences have reported 
that successful clearance of HBV has been shown to be associated with vigorous 
CD4+ T cell response to the nucleocapsid protein, where the kinetics of this response 
is parallel to the CD8+ T response to both the envelope and nucleocapsid proteins 
[37]. There are many studies which use HBV as a model to analyze the physical 
interaction of the HLA system with the pathogen derived peptides, assess the 
possible mechanism underlying HLA class II associations by measuring the binding 
affinities in vitro with the purified HLA-DR1, HLA-DR3, HLA-DR7 and HLA-
DR13 molecules [37]. The peptide binding data validate the obtained results in case 
if there is other important immune response gene in linkage of associate allele related 
to HBV [37].  
Hence, the analysis of physical binding characteristics of overlapping peptides 
derived from HBV proteins to various HLA class II genes offers a mechanistic 
explanation for the dominant CD4+ T cell response during infection [37]. 
Several studies analyzed in healthy patients who had HBV (HBsAg negative, Anti 
HBc Ig G positive, Anti HBs positive) and chronic HBV infection presented that 
specific HLA haplotypes were found to be meaningful, and these were shown to 
increase the risk of chronicity in HBV infection (Table 1.3) [63]. 
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Table 1.3 : HLA Class I Alleles and HBV Persistence [63]. 
HLA I Allele Clinical Situation Country 
A*0206 Chronicity Taiwan 
B-35 Chronicity Taiwan  (Han Chinese) 
A*2 Chronicity Japan 
B18, B35, B40, Cw3 Chronicity Russia 
A3, B18 Chronicity Kazakhs 
 
B8-Cw7 Halpotype HCC Senegal 
B*8 Chronicity U.S. (White) 
A*01-B*08-DRB1*03B*44-
Cw*1601, B*44-Cw*0501  
Chronicity U.S. (White) 
The relationship of HLA antigen with the outcome of HBV infection has been 
demonstrated for several ethnic groups; Gambia, Caucasians, Koreans, and Africans. 
A study in Gambia population (children and adults), showed that the HLA class II 
allele DRB1*1302 was associated with the protection against persistent HBV 
infection [63]. Other data indicate that HLA-DR6, especially HLA-DR13, is one of 
the host factors that influences the immune response to HBV, and may be associated 
with self-elimination of HBV in Koreans [63]. 
In a Chinese Han population, HLA-DQB1*0502, HLA-DQB1*0503 and HLA-
DQB1*0303 allele were shown to be independently related with the outcome of 
HBV infection and mentioned as one host genetic factor affecting the HBV infection 
outcome [63]. Class II gene related studies in many diverse populations displayed 
that HLA-DRB1*13 is associated with viral clearance of HBV, whereas HLA-
DRB1*11/*12 with viral persistence.  
Experiments on HBV vaccine response indicated that especially polymorphisms 
observed in genes of HLA-DR and HLA-DQ are associated with host immune 
response against HBV infection [63]. Furthermore, the polymorphisms in HLA genes 
that affect the immune response are a significant topic in chronic persistence HBV 
infection (Table 1.4-1.6).  
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Table 1.4 : HLA Class II Alleles and HBV Persistence [63]. 
HLA II Allele Clinical Situation Country 
DRB1*1202 Chronicity Taiwan  (Han 
Chinese) 
DQA1*0302 Chronicity China 
DRB1*0301, DQA1*0501,  
DQB1*0301 
Chronicity China 
DR9, DQ9 Chronicity China 
DRB1*06,DRB1*08,DRB1*16 Chronicity China 
DR9 Chronicity Korea 
DQA1*0501, DQB1*0301 Chronicity U.S. (African 
Americans) 
DRB1*1201/1202 Cirrhosis China 
B13,B8, DR7,DR13,DQ3 Chronicity Turkey 
DQA1*0501,DQB1*0301, 
DRB1*1102 haplotype 
Chronicity U.S. (African 
Americans) 
 
Table 1.5 : HLA Class II Alleles and HBV Clearance [63]. 
HLA II Allele Clinical Situation Country 
DRB1*4001 Viral clearance Taiwan 
DRB1*0406, DRB1*0701 Viral clearance Taiwan  (Han 
Chinese) 
DQA1*0301, DQA1*0102 Viral clearance, Inactive Group China 
DRB1*1101/*1104,  
DQA1*0301 
Viral clearance China 
DR6 Viral clearance Korea 
DRB1*1301,DRB1*1302 Viral clearance Gambia 
DQB1*0503 Early e seroconversion Taiwan  (Children) 
DRB1*1301/1302 Viral clearance Spain 
DRB1*1301/1302 Viral clearance Germany 
DR13 Viral clearance Germany 
DRB1*1501/1502 Cirrhosis protection China 
HLA DR5 Without progression disease Japan 
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Table 1.6 : Class II Alleles and Vaccine-Interferon Response [63]. 
HLA II Allele Clinical Situation Country 
DR7 Vaccine – No response Turkey 
DRB1*1302, DQB1*0604 Vaccine – No response Sweden 
DRB1*0701, DQB1*0202 Vaccine – No response England 
DRB1*0101, DRB1*0832,  
DQA1, DQB1, DPA1 
Vaccine response Japan 
DQB1*0301, DQB1*0501 Vaccine response Belgium 
DRB1*1301, DR*15,  
DQB1*0603 
Vaccine response Sweden 
DRB1*11, DQB1*0301 Vaccine response Italy 
DQA1*0501, DQB1*0301 Interferon response China 
DRB1*14 Interferon response China 
DQB1*07 Interferon – No response China 
1.8 Purpose of the Thesis 
In literature, it is presented that HBV infection lead to viral persistence and the 
development of chronic hepatitis B in approximately 15% of adult cases, but still the 
factors that determine the HBV persistence and clearance are not very well 
understood. However, as variety of host conditions such as age of infection, gender, 
and immune response were observed to influence the risk of persistent HBV 
infection and have shown remarkable clinical and pathogenic differences among 
HBV genotypes. The data obtained to date mentions the importance of host immune 
response in determining the outcomes of HBV infection. Moreover, the studies have 
shown the degree of concordance for hepatitis B surface antigen (HBsAg) status 
differs even between monozygotic twins and that most available experimental 
evidence speculated that immune response genes; human leukocyte antigen (HLA) 
class II molecules and cytokine molecules with susceptibility of chronic HBV 
infection are the genetic components of chronic HBV infection [64]. 
Our study, in this line, is concentrated on host immune response of chronic hepatitis 
B virus infection to analyze the association of human leukocyte antigen class II 
molecules (HLADRB1 Alleles) with the clinical outcome of chronic HBV infection 
in Turkish population.  
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For this purpose such chronic hepatitis B patients (N=324) with a control group 
(N=150) were selected and DNA was extracted from peripheral blood, genotyping 
was done via SSP-PCR and agarose gel electrophoresis followed by statistical 
analysis. The obtained genotyping results were compared with Turkish controls. 
Findings from this thesis, in general, aim to understand the relationship between 
immunopathogenesis of chronic hepatitis B infection and HLADRB1 Alleles. 
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2. MATERIAL AND METHODS 
2.1. Materials and Laboratory Equipments 
2.1.1. Used equipments 
The laboratory equipment used for this project is listed in Appendix A. 
2.1.2. Used chemicals, enzymes, markers and buffers 
The chemicals, enzymes and markers used are given in Appendix B together with 
their suppliers. The compositions and preparation of buffers and solutions are shown 
in Appendix C. 
2.2. Selection Criteria of the Chronic Hepatitis B Patients and Control Group 
A total of 324 unrelated Turkish subjects are enrolled in this study, from Department 
of Gastroenterology, Goztepe Teaching and Research Hospital. A case group of 
asymptomatic HBV carriers are recruited according to the results of serological tests 
(HBV virological indexes, liver functional indexes) and symptoms of hepatitis B. 
Chronic hepatitis B is diagnosed if serum levels of alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) are continuously abnormal, with HBsAg 
and/or HBeAg seropositive, anti-HBs antibodies (anti-HBs) seronegative. 
Asymptomatic HBV carriers are identiﬁed with the following diagnostic criteria: 
HBsAg seropositive last for more than 1 year, with normal liver functional indexes 
and without any signs and symptoms of hepatitis and HBV DNA levels are below 
2000 IU.  
The control group is selected from the healthy people of the Goztepe Teaching and 
Research Hospital. The ages of the controls change between 38 and 49 and the 
average is 43,5. The members of the control group have no known history of any 
chronic inflammatory diseases, free from acute or chronic hepatitis B virus infection 
at the time of the study and their functional capacity is sufficient.  
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2.3. Collection and Storage of Blood Samples 
The peripheral blood samples are collected from the patients of Department of 
Gastroenterology, Goztepe Teaching and Research Hospital and chosen as respect to 
the chronic hepatitis B criteria defined previously. The blood samples were collected 
in vacuum tubes with EDTA. The samples are stored at −80 °C. 
2.4 DNA Isolation from Human Whole Blood 
The DNA isolation is done by using Invıtrogen PureLink Genomic DNA Purification 
Kit (Invitrogen).  For each isolation process approximately 1 mL of peripheral blood 
sample is used. The isolated stock DNA is stored at -20 °C. 
2.5 DNA Amount, Purity and Working Solution Calculations 
The concentration and purity of the isolated DNA is calculated due to the absorbance 
values measured at 260, 280 and 320 nm. of the spectrometer. The concentration of 
the DNA is calculated by equation 2.1 and the purity of the DNA samples are 
calculated by equation 2.2 given below: 
 
(2.1) 
 
         (2.2) 
In order to have a set of DNA samples containing same amount of DNA (50 ng/μL), 
dilutions from the stock DNA are prepared (working solutions). The required amount 
of stock DNA solutions is calculated for 500 μL of 50 ng/μL working solutions 
(approximately 25 μg DNA).  
2.6. Single Specific Primer - Polymerase Chain Reaction (SSP-PCR) 
Isolated genomic DNAs of the chronic hepatitis B group are used for PCR reaction. 
The target DNA sequences of the alleles of HLA-DRB1 containing the related SNP 
regions are detected by sequence-speciﬁc primers–polymerase chain reaction (SSP–
PCR) (Olerup et al., 1993). Primers sequences and PCR product sizes are listed in 
FactorDilutionAALngionConcentratDNA 50)()/( 320260
)(
)(
320280
320260
AA
AA
PurityDNA
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Table 2.1. Positive internal control primers with HLA DRB1 speciﬁc primers are 
pooled into reaction system in order to eradicate pseudonegative possibilities. The 
internal control is a fragment of human growth hormone gene 1 (chr 17) with 439 bp. 
The sequences of internal control primers C5 and C3 are also shown in Table 2.1. 
PCR is performed in 25 µL reaction mixture containing 50 ng genomic DNA, 1 U 
DNA Dream Taq Green PCR Master containing, DreamTaq DNA polymerase, 
optimized DreamTaq Green buffer, MgCl2 and dNTPs (Fermentas), 0.2 µm primers, 
0.04 µm internal control primers C5 and C3. The performance of the PCR reaction 
varies due to the purity of the template DNA as well as the amplicon size (length) 
and content (GC%) so PCR conditions are optimized in order to obtain high yield 
and fidelity.   
2.6.1 Oligonucleotide primers 
The oligonucleotide primers used in this study are chosen from previous studies and 
are given in the Table 2.1 below. The confirmation of the actually binding sites, 
binding efficiencies and amplicon sizes is made by Amplify 3X software. 
As it is also essential to analyze the primer sets for dimer formation, the hairpin, 
heterodimer and self dimer analysis of the primer sets are done and confirmed with 
the SciTools on the IDT DNA website (OligoAnalyzer 3.0) 
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Table 2.1 : List of primers used in the study. 
DRB1 alleles Primers PCR 
Product 
DRB1*01 5’ TTGTGGCAGCTTAAGTTTGAAT 3’ 
5’ GCTGTTCCAGTACTCGGCAT 3’ 
168 
DRB1*15/16 5’ TCCTGTGGCAGCCTAAGA G 3’ 
5’ CGCTGCACTGTGAAGCTCTC 3’ 
310 
DRB1*03 5’ GTTTCTTGGAGTACTCTAGGTC 3’ 
5’ TGCAGTAGTTGTCCACCCG 3’ 
222 
DRB1*04 5’ GTTTCTTGGAGCAGGTTAAACA 3’ 
5’ CGCTGCACTGTGAAGCTCTC 3’ 
262 
DRB1*11 5’ CACGTTTCTTGGAGTACTCTAC 3’ 
5’ CTGGCTGTTCCAGTACTCCT 3’ 
179 
DRB1*12 5’ AGTACTCTACGGGTGAGTGTT 3’ 
5’ CTGTTCCAGGACTCGGCGA 3’ 
198 
DRB1*13/14 5’ GTTTCTTGGAGTACTCTACGTC 3’ 
5’ CGTAGTTGTGTCTGCA(GA)TAGG 3’ 
234 
DRB1*07 5’ CCTGTGGCAGGG AAGTATA 3’ 
5’ CCCGTAGTTGTGTCTGCACAC 3’ 
232 
DRB1*08 5’ AGTACTCTACGGGTGAGTGTT 3’ 
5’ CCCGTATTGTGTCTGCAG 3’ 
227 
DRB1*09 5’ GTTTCTTGAAGCAGGATAAGTTT3’ 
5’ CCCGTAGTTGTGTCTGCACAC 3’ 
236 
DRB1*10 5’ CGGTTGCTGGAAAGACGCG 3’ 
5’ CTGCACTGTGAAGCT CTCAC 3’ 
204 
DRB1-Exon2 5’ TTCGTGTCCCCACAGCACGTTTC 3’ 
5’ GCCGCTGCACTGTGAAGCTCTC 3’ 
295 
Internal Control 
(HGH) 
5′ CAGTGCCTTCCCAACCATTCCCTTA 3′ 
5’ATCCACTCACGGATTTCTGTTGTGTTTC 3′ 
439 
 
2.6.2 PCR cycle conditions 
The PCR cycle conditions are varied according to the desired amplicon. The only 
variable in the PCR cycle conditions is the annealing temperatures, caused by the 
usage of different primer sets (Table 2.2).  
 
 
 
27 
 
Table 2.2 : General PCR cycle conditions. 
Repeat 
Number 
Degree Time Phase 
1 
94 °C  5 minutes  Initial Denaturation  
35 
94 °C  1 minutes  Denaturation  
Variable 60 seconds Annealing  
72 °C  4 minutes Extension  
1 
72 °C  8 minutes  Final Extension  
 
2.6.3 PCR optimization 
Generally, PCR reactions are required optimization for higher performance related 
with the amplification of the correct target and determination of appropriate 
annealing temperature for different primer sets. In this thesis, PCR conditions are 
optimized via gradient PCR methods. 
2.6.4 Gradient PCR 
It might be necessary to use gradient PCR to determine the optimum annealing 
temperature for a PCR reaction when appropriate annealing temperature is not 
known for a primer set. In gradient PCR, the thermo cycler is set in such a way that 
the wells in the thermo cycler block have a gradient of temperature from high to low 
for the annealing phase of the cycles. So, gradient PCR allows the run of a set of 
identical PCR in the same block with different annealing temperatures, which saves 
time and prevents multiple usage of the thermo cycler for the same optimization.  
After analyzing the PCR products with agarose gel electrophoresis, annealing 
temperature of the PCR mixture that gives the best band intensity is chosen as the 
optimum annealing temperature. In this thesis, the optimization of the annealing 
temperature of specific SNP PCR is made by gradient PCR by forming a gradient 
from 65 to 72 and the best band intensity is seen for 65°C, so this temperature is used 
as the annealing temperature of HLA alleles PCR for the rest of the studies. 
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2.7 PCR Conditions of HLA DR Alleles 
The PCR conditions for the HLA DR polymorphism is shown in the table 2.2 below. 
Table 2.3 : PCR conditions for the HLA DR polymorphisms. 
Repeat 
Number  
Degree  Time  Phase  
  
1 94 °C  5 minutes  Initial Denaturation  
35 
94 °C  1 minutes  Denaturation  
65 °C 60 seconds Annealing  
72 °C  4 minutes Extension  
1 72 °C  8 minutes  Final Extension  
2.8 Agarose Gel Electrophoresis of PCR Products 
The right percentage of an agarose gel is beneficial for observing the PCR bands 
accurately. In this thesis, the PCR products of amplicon sizes can be seen on a 2% 
agarose gel. PCR products is observed either on 2% mini gels prepared with 2.0 g 
agarose into 100 mL of 1X TAE buffer, which is diluted from 50X stock TAE . 6 μL 
of PCR product is mixed with 1 μL 6X loading dye and with 1 μL SyberGreen in 
order to load into the wells. Lengths of the PCR products are calculated according to 
O‟Range GeneRuler Low Range marker (Fermentas) and O‟Range GeneRuler Ultra 
Low Range marker (Fermentas). The gels are run in 1X TAE buffer, at 80V with 
power supplier, for at least 45 minutes. The observations of the gels under UV light 
are made by transilluminator and UV PhotoMW software is used in order to take the 
photos of the gels. 
2.9 Genotyping 
The genotyping is done by analyzing the agarose gel photos of SSP PCR products for 
the all HLA DRB1 alleles observed in patients, respectively. O‟Range GeneRuler 
LowRange (Fermentas) or O‟Range GeneRuler Ultra LowRange (Fermentas) 
markers are also loaded to decide the band sizes along with positive controls. Indeed, 
the allelic type was determined according to the presence or absence of the desired 
length PCR products. 
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2.10 Statistical Analysis 
In this study, in order to analyze the effect of HLA DRB1 alleles in patients with 
chronic hepatitis B infection statistical analysis were performed. A 2 × 2 contingency 
table was used to compare alleles‟ frequencies according to clinical statues of the 
patients. All statistical analyses were performed using the SPSS program, version 17 
(SPSS, Chiacago, IL). Distribution of quantitative data was evaluated by Kolmogrof-
Smirnov test in order to understand if the data conform to or not Gaussien 
distribution. Quantitative data that conform to Gaussien distribution was evaluated 
by Student t test, whereas the data that does not match to Gaussien distribution or do 
not fulfill parametric conditions was appraised by Mann Whitney U test. Analysis of 
categorical data and HLA alleles, where 2 × 2 contingency table was used, 
statistically were performed by χ2 test.  In case of expecting any data bellow 5 in any 
cell in 2 × 2 contingency table, Fisher‟s exact test was used . In all analysis two-sided 
p was taken into account and if p<0.05 it was considered as significant.  
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3. RESULTS 
3.1 Demographic Data of the Chronic Hepatitis B Group 
In this study 324 patients were included; 63.4% male (n=204), 36.4% female and, 
where 23.5% (n=76) of patients being HBe antigen positive, 23.8% (n=77) having 
cirrhosis (Table 3.1). The median age was 44.4 years, median follow up time was 
86.5 months. In the control group 150 healthy cases were included (DRB1*07).  
Table 3.1 : Demographic data of all patients. 
 n (%)  
Sex  Male  204 (63.4)  
Female  120 (36.6)  
HBeAg  Negative  248 (76.5) 
Positive  76 (23.5)  
Cirrhosis  yes 77 (23.8)  
no 247 (76.2) 
 
From the total of 324 patients 198 had a course of lamivudine or adefovir treatment. 
Of those 96 patients had virologic breakthrough during these treatments. The rest of 
the patients responded well to the given treatment without any virologic resistance. 
In our group of patients, 115 had interferon experience. Only 19 of them responded 
to interferon treatment. 
Fifty-nine patients had inactive disease with persistently normal liver tests and all 
HBV DNA measurements during follow up for these patients were below 2000 IU. 
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3.2 DNA Isolation Results 
In this thesis, DNA isolation is done according to the procedure provided by 
Invitrogen PureLink Genomic DNA Purification Kit. The average DNA 
concentration obtained from kit is 251 ng/μL and average A260/A280 value is 1.8 
(N=324). 
3.3 Genotype Analysis 
The genotyping is done by comparing the bands on the agarose gel. Some samples of 
PCR results for SNP analysis are shown in Figures 3.1, and 3.2. 
Figure 3.1 shows internal control (HGH) together with DRB1*08 and DRB1*09 
from blood samples. M shows size marker DNA (100-bp DNA ladder); N, negative 
control; 1–5 lines show each number of amplified HGH products (Internal control 
>450bp). As observed from the figure all of the internal controls gave a band at the 
appropriate DNA size (Figure 3.1) worked. There was not seen an observation of 
DRB1*08 and DRB1*09 alleles on the lines 1-5 in the patients of chronic HBV 
infection which were loaded together with internal control. The number on the right 
indicates the molecular size (in base pairs) of the amplified PCR products. 
Figure 3.1 : Agarose gel electrophoresis analysis on 2.0% agarose gel for the target DNA sequences 
such as targeted internal control (HGH), DRB1*08 and DRB1*09 from blood samples. 
Lanes: M, size marker DNA (100-bp DNA ladder); N, negative control; 1–5, each 
number of amplified HGH products (Internal control >450bp). The number on the right 
indicates the molecular size (in base pairs) of the amplified PCR products. 
At the same time all other 8 HLA-DRB1 alleles (DRB1*01, DRB1*15/16, 
DRB1*03, DRB1*04, DRB1*11, DRB1*12, DRB1*13/14/11, DRB1*10) were 
analyzed on agarose gel electrophoresis. 
33 
 
From our genotyping analysis, we found the most significant relation of chronic 
HBV infection with DRB1*07 allele. In Figure 3.2, some of the patients DNAs were 
scanned using the primers specific for DRB1*07 allele. It can be observed from the 
figure that there are two bands for the internal control HGH (450bp) and DRB1*07 
allele (232bp) (Figure 3.2). 
Figure 3.2 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA sequences amplified 
by polymerase chain reaction (PCR) assay by using outer and inner primer sets targeting 
DRB1*07 from blood samples. Lanes: M, size marker DNA (100 bp DNA ladder); 1–24 
lines show each number of amplified DRB1*07 (232bp DNA fragment), N shows 
negative control; 450bp bands show  internal control. 
3.4 HLA Results 
HLA-DRB1 alleles in 324 patients with chronic hepatitis B and 150 healthy cases 
were analyzed using the polymerase chain reaction/sequence specific primer 
(PCR/SSP) technique. 
The table bellow shows the distribution of allele frequencies used in our study. 
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Table 3.2 : Allele frequencies. 
 n % 
DRB1*01 0 0 
DRB1*15/16 63 19.4 
DRB1*03 24 7.4 
DRB1*04 0 0 
DRB1*11 0 0 
DRB1*12 23 7.1 
DRB1*13/14 177 54.6 
DRB1*07 24 7.4 
DRB1*08 0 0 
DRB1*09 0 0 
DRB1*10 12 3.7 
 
In our group of patients B1*13/14 allele was the most frequent (54.6%). The 
frequencies of the other alleles were given in the table (Table 3.2).  
When we analyze the relation of the alleles according to clinical status of the 
patients; our data demonstrate that DRB1 alleles were not related to the active or 
inactive disease, or interferon treatment response or virologic breakthroughs 
observed during nucleoside analog treatments.  
On the other hand we have found statistically significant frequency of DRB1*07 
allele (p=0.003) in our case-control study (Table 3.3). Moreover, our data showed 
that, patients who had DRB1*07 allele had lower probability to have cirrhosis 
(likelihood ratio chi square: 4.17, p=0.04), suggesting that DRB1*07 might be 
associated with low risk of cirrhosis development (Table 3.4).  
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Table 3.3 : Statistical analysis of HLA-DRB1*07 allele frequencies of chronic HBV infected patients 
and control group. 
 
 
Patients (n=324)  
Controls 
(145)  
χ2  †  p  OR  95% CI  
 
DRB1*07 
 
24 (7.4)  
 
2 (1.4)  
 
8.6 
 
0.003* 
 
0.17 
 
0.04-0.75  
 
Table 3.4 : Statistical analysis of HLA-DRB1 allele frequencies of chronic HBV infected patients. 
 
 
Cirrhosis present  
n=77(%)  
No 
cirrhosis 
n=247(%)  
χ2  †  p  OR  95% CI  
DRB1*15/16  12 (15)  51(20.6)  0.99  0.32  0.71  0.36-1.41  
DRB1*03  3 (3.9)  21 (8.5)  2.1  0.15  0.43  0.13-1.5  
DRB1*12  3(3.9)  20(8.1)  1.78  0.18  0.46  0.13-1.59  
DRB1*13/14  42 (54.5)  135(54.7)  0  0.99  0.99  0.59-1.66  
DRB1*07  2 (2.6)  22 (8.9)  4.17  0.04 * 0.27  0.06-1.19  
DRB1*10  3(3.9)  9(3.6)  0.01  0.9  1.07  0.28-4.06  
 
In this case, our results demonstrate that DRB1*07 allele may be one of the host 
factors, which influences immune response to HBV, by self-limiting cirrhosis, one of 
the main complications of chronic HBV.  
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4. DISCUSSION 
About 50-60% of HBeAg positive and negative hepatitis B patients respond to 
medication by several drugs such as Lamivudine, Adefovir dipivoxil, Interferon. 
Experimental evidence in many articles for the negativity of HBV DNA in patients 
with HBV treated with tenofovir (Tdf) and entecavir (Etv) showed a percentage 
above 90. HBeAg negative patients treated with PEGylated interferon alpha-2a 
showed about 25% negativity of HBV DNA, 34% seroconversion, and about 3% loss 
of HBsAg, where after the third year 20% of patients show a HBV DNA level below 
400 copies. The optimal duration of therapy is not yet clear, moreover, the usage of 
drugs during the treatment of HBV infection is observed to lead to resistance, that is 
one of the main handicaps of the clearance of virus. The reasons for defective viral 
clearance are not completely understood. Treatment of chronic hepatitis B virus 
infection, even in the presence of approved drugs for adults and many promising new 
drugs in development, is still a serious issue due to the absence of a complete cure 
for hepatitis B infection 
On the other hand, host and viral factors (HLA polymorphisms & viral genotypes) 
undoubtedly influencing the outcomes of HBV infections, respectively, have shown 
their importance in the progression of HBV infection and available experimental 
evidence speculated that immune response genes; human leukocyte antigen (HLA) 
class II molecules and cytokine molecules with susceptibility of chronic HBV 
infection are the genetic components of chronic HBV infection.
[64]
 Hence, the aim of 
the present work was to ascertain whether specific HLA-DRB1 alleles are associated 
with the outcomes of HBV infection in the Turkish population. In our study, 
frequencies of the 12 specific HLA-DRB1 (Table 2.1) allele polymorphisms were 
analyzed in patients with HBV infection. The obtained data from the present study 
show a statistically significant association between DRB1*07 allele and presence of 
cirrhosis in patients with chronic HBV infection.  
Patients who had DRB1*07 allele had lower probability to have cirrhosis (likelihood 
ratio chi square: 4.17, p=0.04). Moreover, we have found statistically significant 
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frequency of DRB1*07 allele (p=0.003) in our case-control study supporting the role 
of DRB1*07 allele in the development of cirrhosis.  
In this case, we suggest that DRB1*07 allele may be one of the host factors, which 
influences immune response to HBV, by self-limiting cirrhosis, one of the main 
complications of chronic HBV.  
In several studies HLA-DRB1*07 allele was shown to be associated with many 
disorders. For instance a study done in Turkish population have shown the 
association of HLA-DRB1*07 allele with vitiligo, a pigmentary disorder affecting 
approximetaly 0.38-1.13% people in distinct areas of the world. This study strongly 
suggested that HLA-DRB1*07 may be one of the genetic markers for general 
susceptibility to vitiligo in a Turkish population (p=0.0004) [66].
 
Another study, in 
Pakistan presented that HLA-DRB1*07 (p=0.008) individually or in combination 
with HLA-DQB1*02 was found to be associated with viral persistence of HCV 
infection, following IFN therapy, where the long term viral persistance of this virus 
lead to liver cirhossis [67].
 
HLA-DRB1*07 was also emphasized as an susceptible 
allele for the occurrence of autoimmune hepatitis type 2 by a study done in children 
with autoimmune hepatitis [68]. A meta-analysis done by Xuan, S.Y. and his friends 
showed that among the 3 HLA-DRB1 alleles studied, DRB1*07 and DRB1*12 were 
significantly associated with the risk of HCC in the Chinese whole populations. This 
study emphasizes the significante of DRB1*07 in HBV infection.  
As we know in the patients with chronic hepatitis B virus infection, there is an 
observation of decreased level of CD4+ and CD8+ immune response, where it is 
thought that increased level of HBeAg and HBsAg antigens may be the reason of this 
immune response. Our hypothesis contrasts to the previously suggested hypothesis 
based on antigen type. Parallel to the literature ideas, we think that the presence of 
substitutions on the HLADRB1*07 T-cell recognition residues causes weak 
interactions to the T-cells in patients with HBV infection. This type of HLA class II 
molecules show highly polymorphic character in the T-cell recognition as explained 
in part of introduction 1.6 [69].
 
Also crystallographic studies reveal that T-cell 
recognition is associated with the HLA class II molecules rather than the antigens 
[36]. 
39 
 
Therefore weak immune response of the patients carrying HLA-DRB1*07 allele is 
based basically on the type of allele present.  
HLA class II glycoproteins, encoded by HLA-DRB1 molecules such as DRB1*07 
present viral peptides to CD4+ T cells and thus influence the immune response. So 
we believe that HLA-DRB1*07 allele may be the key host factor to determine the 
development of diseases from HBV infection to cirrhosis in Turkish population. This 
is mainly based on the results obtained from our patients who had DRB1*07 allele 
showing lower probability for cirrhosis. Proposed role of DRB1*07 should be 
validated with a further molecular approaches. Analysing of all variants of HLA-
DRB1 molecules together with screening of T cell condition not only in patients with 
HBV infection but also in patients who had recovered from HBV infection 
conducted by a control group will help us to illuminate the mechanism of disease.  
On the other hand, the results of analyzed frequencies of other specific HLA-DRB1 
alleles were not related to active or inactive disease, or interferon treatment response 
or virologic breakthroughs observed during nucleoside analog treatments.  
Whereas, recently our study group demonstrated a relation between DQB1*0501 
allele and chronic active disease; DQB1*0301/4 allele and interferon response; 
DQB1*0503 and virologic breakthrough during antiviral treatments [65]. 
Another study done in Gambia population (children&adults), showed that the HLA 
class II allele DRB1*1302 was associated with the protection against persistent HBV 
infection. Other data indicate that HLA-DR6, especially HLA-DR13, is one of the 
host factors that influences the immune response to HBV, and may be associated 
with self-elimination of HBV in Koreans.  
In a Chinese Han population, HLA-DQB1*0502, HLA-DQB1*0503 and HLA-
DQB1*0303 allele were showed to be independently related with the outcome of 
HBV infection and mentioned as one host genetic factor affecting HBV infection 
outcome. Class II HLA gene related studies in many diverse populations displayed 
that HLA-DRB1*13 is associated with viral clearance, whereas HLA-DRB1*11/*12 
with viral persistence. A study in northwestern China showed that the allele 
frequencies of HLA-DRB1*03 and HLA-DRB1*07 were markedly higher in the 
HBV-infected group but the allele frequencies of HLA-DRB1*15 were obviously 
lower than that of the spontaneously cleared controls. Although, previous reports 
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mentioned above found that specific HLA-DRB1 alleles were significantly more 
frequent in hepatitis B carriers and patients of chronic hepatitis B infection, this was 
not the case in the present study. A primary cause for the difference in results 
between data by different authors and our results may be related to the great 
variability of the frequency of HLA alleles in different populations, where it is quite 
possible that one ethnic group may have some specific alleles in 
development/protection of chronic hepatitis B, respectively cirrhosis compared to 
other ethnic groups. 
Furthermore, studies conducted on relatively small scale may affect the results by 
decreasing the power of detection of difference in the distribution of specific HLA-
DRB1 alleles between chronic hepatitis B patients and controls, even a true 
difference exists. To highlight the association of HLA class I and II genes in the 
progression of HBV infection, not only the alleles that are thought to influence the T 
cells response but also a linked polymorphism in a neighboring immunoregulatory 
gene has to be taken into account. Additionally, other genetic factors in linkage 
disequilibrum with HLA class I and II might influence the clearance of chronic HBV 
infection in Turkish population, so lack of an association may not mean that 
associations do not exist. 
In conclusion, individuals with distinct HLA types may differ in susceptibility or 
resistance to disease and large, multi-ethnic confirmatory study is needed to validate 
these findings and to further explore the genetic pathogenesis of HBV infection.  
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APPENDIX A 
LABORATORY EQUIPMENT 
Balances           Precisa 620C SCS 
            Precisa BJ 610C 
Centrifuges           Sigma 1-13 B. Braun International 
            Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments        E – C mini cell primo EC320 
Gel Documentation System         UVI PhotoMW Version 99.05 for Windows 
Pipettes           Thermo Finnpipette 10 µL, 100 μl, 1000 μl 
pH meter           Mettler Toledo MP220 
Spectrophotometer          PerkinElmer Lambda25 UV/VIS 
Spectrometer 
Thermo cycler          Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator         Biorad UV Transilluminator 2000 
Vortex          Herdolph Reax top  
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APPENDIX B 
CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol    Riedel-de Haën 
SYBR     Fermentas 
MgCl2     Fermentas 
NaOH     Riedel-de Haën 
Primers    IDT DNA 
NaCl     Carlo Erba 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
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APPENDIX C 
BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
 
Mini Agarose Gel (2%)  
Agarose     1.0 g 
TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (2%)  
Agarose     3.0 g 
TBE buffer (1X)   150 mL 
 
Mini Agarose Gel (4%)  
Agarose     2 g 
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TBE buffer (1X)   50 mL 
 
Midi Agarose Gel (4%)  
Agarose    6 g 
TBE buffer (1X)   150 mL 
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APPENDIX D 
 
Figure D.1 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*09 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); 5 and 9 
lines show each number of amplified DRB1*09 (236bp DNA 
fragment), 1-13 lines shows each number of amplified HGH internal 
control (450bp). 
 
Figure D.2 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*08 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); 3, 7 and 8 
lines show each number of amplified DRB1*08 (227 bp DNA 
fragment), 1-17 lines shows each number of amplified HGH internal 
control (450bp); N shows negative control. 
 
 
56 
 
 
 
Figure D.3 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*13/14 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); The 8 line 
shows number of amplified DRB1*13/14 (234 bp DNA fragment), 1-11 
lines shows each number of amplified HGH internal control (450bp). 
Figure D.4 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*10 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); The 6 line 
shows number of amplified DRB1*10 (204 bp DNA fragment), 1-9 
lines shows each number of amplified HGH internal control (450bp). 
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Figure D.5 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*10 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); The 5, 8-9 
line show number of amplified DRB1*03 (222 bp DNA fragment), 1-10 
lines shows each number of amplified HGH internal control (450bp). 
 
Figure D.6 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*15/16 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); The 6 line 
shows number of amplified DRB1*15/16 (310 bp DNA fragment), 1-10 
lines shows each number of amplified HGH internal control (450bp). 
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Figure D.7 : Agarose gel electrophoresis analysis on 2.0% agarose gel of DNA 
sequences amplified by polymerase chain reaction (PCR) assay by 
using outer and inner primer sets targeting DRB1*12 from blood 
samples. Lanes: M, size marker DNA (100-bp DNA ladder); The 1, 5, 
7, 8 lines show number of amplified DRB1*12 (198 bp DNA 
fragment), 1-10 lines shows each number of amplified HGH internal 
control (450bp). 
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APPENDIX E 
ENZYMES 
DreamTaq DNA Polymerase  Fermentas 
                 Invitrogen 
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APPENDIX F 
MARKERS 
O’Gene RulerTM DNA Ladder Low Range  Fermentas 
 
 
O’Gene RulerTM DNA Ladder Ultra Low Range  Fermentas 
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